Associated Papers
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.
Wei L et al.
Molecular Therapy Oncolytics, 2020
Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia.
Watanabe-Smith K et al.
Leukemia, 2016
27118405 (PubMed )
Supplement: NIHMS777047-supplement-2.xlsx › Sheet1
Select a paper to view details